Projected Impact of HPV and LBC Primary Testing on Rates of Referral for Colposcopy in a Canadian Cervical Cancer Screening Program (Q40744526)

23 September 2017

title

Projected Impact of HPV and LBC Primary Testing on Rates of Referral for Colposcopy in a Canadian Cervical Cancer Screening Program (English)

1 reference

23 September 2017

1 reference

14

1 reference

23 September 2017

Stuart Peacock

11

0 references

Eduardo L. Franco

object named as

Eduardo L Franco

13

0 references

Mel Krajden

5

object named as

Mel Krajden

1 reference

23 September 2017

Andrew J Coldman

1

1 reference

23 September 2017

Norm Phillips

2

1 reference

23 September 2017

Dirk van Niekerk

3

1 reference

23 September 2017

Laurie Smith

4

1 reference

23 September 2017

Darrel Cook

6

1 reference

23 September 2017

David J Quinlan

7

1 reference

23 September 2017

Thomas Ehlen

8

1 reference

23 September 2017

Dianne Miller

9

1 reference

23 September 2017

Gavin C E Stuart

10

1 reference

23 September 2017

Ruth Elwood Martin

12

1 reference

23 September 2017

publication date

1 May 2015

1 reference

Journal of Obstetrics and Gynaecology Canada

23 September 2017

published in

1 reference

23 September 2017

volume

37

1 reference

23 September 2017

issue

5

1 reference

23 September 2017

page(s)

412-420

1 reference

Could HPV testing become the sole primary cervical screening test?

23 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2815%2930255-3

7 January 2021

Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2815%2930255-3

7 January 2021

Eurogin 2010 roadmap on cervical cancer prevention

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2815%2930255-3

7 January 2021

Overview of the European and North American studies on HPV testing in primary cervical cancer screening

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2815%2930255-3

7 January 2021

Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2815%2930255-3

7 January 2021

Extended duration of the detectable stage by adding HPV test in cervical cancer screening

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2815%2930255-3

7 January 2021

Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2815%2930255-3

7 January 2021

Colposcopic and histopathologic evaluation of women participating in population-based screening for human papillomavirus deoxyribonucleic acid persistence.

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2815%2930255-3

7 January 2021

HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2815%2930255-3

7 January 2021

Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: prospective randomised trial in Finland

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2815%2930255-3

7 January 2021

Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2815%2930255-3

7 January 2021

Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2815%2930255-3

7 January 2021

Recommendations on screening for cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2815%2930255-3

7 January 2021

Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial -- the HPV FOCAL Study

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2815%2930255-3

7 January 2021

Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2815%2930255-3

7 January 2021

Primary human papillomavirus testing in organized cervical screening

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2815%2930255-3

7 January 2021

A randomized controlled trial of Human Papillomavirus (HPV) testing for cervical cancer screening: trial design and preliminary results (HPV FOCAL Trial)

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2815%2930255-3

7 January 2021

The 2001 Bethesda System: terminology for reporting results of cervical cytology

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2815%2930255-3

7 January 2021

Organisation and results of the cervical cytology screening programme in British Columbia, 1955-85.

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2815%2930255-3

7 January 2021

Management of women who test positive for high-risk types of human papillomavirus: the HART study

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2815%2930255-3

7 January 2021

POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2815%2930255-3

7 January 2021

American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2815%2930255-3

7 January 2021

The expected impact of HPV vaccination on the accuracy of cervical cancer screening: the need for a paradigm change

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2815%2930255-3

7 January 2021

Increased risk of preterm birth after treatment for CIN

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2815%2930255-3

7 January 2021

Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2815%2930255-3

7 January 2021

Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2815%2930255-3

7 January 2021

Risk of preterm birth after treatment for cervical intraepithelial neoplasia among women attending colposcopy in England: retrospective-prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2815%2930255-3

7 January 2021

A DNA methylation classifier of cervical precancer based on human papillomavirus and human genes

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2815%2930255-3

7 January 2021

10.1016/S1701-2163(15)30255-3

Identifiers

DOI

1 reference

23 September 2017

1 reference